558P Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 34; p. S1687
Main Authors	Lee, J.E., Nam, J.H., Kwon, S.H., Kim, B-K., Ha, S-M.
Format	Journal Article
Language	English
Published	01.11.2023
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2023.10.636